Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular
hypertension will undergo screening and washout from IOP-lowering medication, if applicable.
Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who
undergo successful cataract extraction with implantation of a posterior chamber intraocular
lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.